VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vanda Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.09+0.06 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Vanda Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $247.29M | $166.30M |
| Enterprise Value | $191.41M | $88.19M |
| PS Ratio | 1.15 | 3.65 |
| PB Ratio | 1.12 | 2.03 |
| P/TBV Ratio | 2.31 | 2.29 |
Enterprise value
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 0.89 | 2.51 |
Income (trailing twelve months)
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $215.72M | $58.34M |
| Gross Profit | $202.22M | $105.94M |
| Operating Income | -$185.67M | -$21.40M |
| Pretax Income | -$177.20M | -$14.34M |
| Net Income | -$274.85M | -$22.46M |
| EBITDA | -$185.67M | -$16.91M |
| EPS (Diluted) | -$4.63 | -$0.83 |
Margins
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 93.7% | 52.9% |
| Operating Margin | -86.1% | -44.0% |
| Pretax Margin | -82.1% | -13.3% |
| Profit Margin | -127.4% | -40.2% |
| EBITDA Margin | -86.1% | -30.2% |
| FCF Margin | -66.3% | -9.27% |
Returns
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -77.8% | -53.2% |
| Return on Assets (ROA) | -53.0% | -40.9% |
| Return on Invested Capital (ROIC) | -51.5% | -32.4% |
| Return on Capital Employed (ROCE) | -74.7% | -38.1% |
Growth
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.02% | 5.96% |
| Revenue Growth (3Y CAGR) | -5.29% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.73% | 6.48% |
Balance sheet
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $55.88M | $61.43M |
| Net Cash (Debt) | $55.88M | $15.35M |
| Net Cash Per Share | $0.92 | $0.66 |
| Equity (Book Value) | $220.19M | $49.09M |
| Book Value Per Share | $3.64 | $1.37 |
| Tangible Book Value | $107.07M | $23.52M |
| Working Capital | $100.46M | $76.81M |
Financial position
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.61 | 3.34 |
| Quick Ratio | 0.70 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$142.33M | -$12.35M |
| Capital Expenditures | -$674.00K | -$1.08M |
| Free Cash Flow | -$143.01M | -$20.22M |
| FCF Per Share | -$2.37 | -$0.42 |
Efficiency
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.42 | 0.39 |
| Inventory Turnover | 7.02 | 2.70 |
| Revenue Per Employee | $404.73K | $404.87K |
| Profits Per Employee | -$515.67K | -$703.34K |
| Employee Count | 533 | 74 |
Dividends and yields
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -111.1% | -23.3% |
| FCF Yield | -57.8% | -8.72% |
Shares
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 60,462,700 | 58,127,000 |
| Shares Change (YoY) | 1.62% | 10.9% |
| Shares Change (QoQ) | 0.53% | 0.54% |
| Float | 54,900,400 | 49,136,700 |
| Shares Held by Insiders | 9.20% | 11.6% |
| Shares Held by Institutions | 82.2% | 59.4% |
Taxes
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $97.65M | $79.87K |
Scores
| Measure | Vanda Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -1.62 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Vanda Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.